At a glance
ClinicalIndex Comparison RecordN/AUnknown· 60 target
Drug / intervention
pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study of Constructing Immune Repertoire Using Next-generation Sequencing (NGS) to Monitor the Therapeutic Effect in NSCLC Patients
In Brief
An observational study evaluating pembrolizumab for Non-small Cell Lung Cancer. Targeting 60 participants across 1 site.
Detailed Summary
This study is designed to evaluate the untreated NSCLC patients. After participants have accepted chemotherapy, radiotherapy, and immunotherapy, the investigators used the next generation sequence technology (NGS) to construct immune repertoire to detective variation of patients' immune state and to monitor patients' therapeutic effect. The investigators are aim to explore the novel clone sequence as potential therapy target.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
CollaboratorsGeneplus-Beijing Co. Ltd.
Timeline
N/AUnknownOverdue
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionJul 2021
Study CompletionDec 2021
TodayJul 2026
First PostedDec 14, 2017
Enrollment StartNov 23, 2017
Primary CompletionJul 31, 2021
Study CompletionDec 31, 2021
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 8.5 years ago
Interventions
pembrolizumabdrug
anti-programmed death 1 (PD-1) antibody